PUBLIC COMPANY
save$CORTCORCEPT THERAPEUTICS INC
$CORT117.17+2.36%Redwood City, CA, USupdated 2h ago
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.
community read0 votes
pipeline
2
marketed
2
phase 3
0
catalysts ytd
4
approvals ytd
1
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (2)
Active trials
- phase2Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- phase2Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
- phase2Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
- phase1Evaluating the Pharmacokinetics and Safety of Miricorilant
- phase2Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
- phase2A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
- phase1Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects
- phase2Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 7, 26SELLGuyer William· Chief Development Officer−$819K↗
- Mar 25, 26SELLBELANOFF JOSEPH K· Chief Executive Officer−$1.31M↗
- Mar 20, 26SELLGuyer William· Chief Development Officer−$424K↗
- Mar 17, 26BUYBAKER G LEONARD JR· $2.50M↗
- Mar 17, 26BUYBAKER G LEONARD JR· $813K↗
- Mar 4, 26SELLGuyer William· Chief Development Officer−$296K↗
routine RSU / option mechanics (6)
- Apr 22, 26giftWILSON JAMES N · director2,000 sh
- Apr 7, 26option exerciseGuyer William · Chief Development Officer20,000 sh
- Apr 7, 26option exerciseGuyer William · Chief Development Officer20,000 sh
- Apr 6, 26giftWILSON JAMES N · director5,000 sh
- Mar 20, 26option exerciseGuyer William · Chief Development Officer11,767 sh
- Mar 20, 26giftWILSON JAMES N · director4,000 sh
🐶 Hiring Signal
News
- Pfizer CFO to depart; GSK wins approval for UTI drugPlus news about Apellis Pharmaceuticals, Servier, TORL BioTherapeutics, Verastem, Corcept Therapeutics, Legend Biotech, COUR Pharmaceuticals, cAMPfield Therapeutics and LabGenius Therapeutics. 👋 P…endpoints · 2mo ago
- Giants of Cancer Care Announces the 14th Annual Class of Inducteesonclive · 3mo ago
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that